{"id":"NCT01206660","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis","officialTitle":"A Double-Blind, Vehicle-Controlled, Randomized, Parallel Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone 0.25% Topical Spray in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2010-12","completion":"2011-01","firstPosted":"2010-09-22","resultsPosted":"2014-07-03","lastUpdate":"2014-07-03"},"enrollment":120,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Desoximetasone Spray 0.25%","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Desoximetasone Spray 0.25%","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.","primaryOutcome":{"measure":"Clinical Success ITT","timeFrame":"28 days","effectByArm":[{"arm":"Desoximetasone Spray 0.25%","deltaMin":32,"sd":null},{"arm":"Placebo","deltaMin":11,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Application Site Irritation","Application Site Pain"]}}